Scarica l'app Stockscreener
101.35
1.66%
-1.71
Dopo l'orario di chiusura:
101.35
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BPMC Giù?
Forum
Previsione
Precedente Chiudi:
$103.06
Aprire:
$103.17
Volume 24 ore:
901.72K
Relative Volume:
0.96
Capitalizzazione di mercato:
$6.55B
Reddito:
$434.41M
Utile/perdita netta:
$-128.05M
Rapporto P/E:
-48.03
EPS:
-2.11
Flusso di cassa netto:
$-250.52M
1 W Prestazione:
-0.15%
1M Prestazione:
+14.55%
6M Prestazione:
+5.16%
1 anno Prestazione:
-4.71%
Intervallo 1D:
$100.57
$103.17
Intervallo di 1 settimana:
$94.38
$103.17
Portata 52W:
$73.04
$121.90
Blueprint Medicines Corp Stock (BPMC) Company Profile
Nome
Blueprint Medicines Corp
Settore
Industria
Telefono
617-374-7580
Indirizzo
45 SIDNEY STREET, CAMBRIDGE, MA
Confronta BPMC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
101.35 | 6.56B | 434.41M | -128.05M | -250.52M | -2.11 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-20 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-03-18 | Iniziato | Wolfe Research | Outperform |
| 2025-03-17 | Iniziato | Jefferies | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-11-14 | Iniziato | JP Morgan | Overweight |
| 2024-10-24 | Iniziato | UBS | Neutral |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2024-05-06 | Aggiornamento | Leerink Partners | Underperform → Market Perform |
| 2023-10-27 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-08-21 | Reiterato | Needham | Buy |
| 2023-07-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-05 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2023-01-03 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-11-02 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-09-14 | Iniziato | Berenberg | Buy |
| 2022-07-08 | Iniziato | Oppenheimer | Outperform |
| 2022-06-27 | Iniziato | Wells Fargo | Underweight |
| 2022-06-10 | Downgrade | Citigroup | Neutral → Sell |
| 2022-06-01 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-01 | Iniziato | Citigroup | Neutral |
| 2022-02-17 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-01-25 | Aggiornamento | Stifel | Hold → Buy |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-09-30 | Ripresa | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-31 | Iniziato | Credit Suisse | Neutral |
| 2020-12-03 | Iniziato | Stifel | Hold |
| 2020-11-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-02 | Downgrade | Jefferies | Buy → Hold |
| 2020-10-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-15 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-05 | Iniziato | Barclays | Equal Weight |
| 2020-03-17 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-11-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-10-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-03 | Iniziato | H.C. Wainwright | Buy |
| 2019-09-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-08-29 | Iniziato | Piper Jaffray | Neutral |
| 2019-08-15 | Ripresa | Raymond James | Mkt Perform |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2019-05-23 | Ripresa | Goldman | Buy |
| 2019-04-03 | Iniziato | Morgan Stanley | Overweight |
| 2018-09-25 | Iniziato | Leerink Partners | Outperform |
| 2017-12-11 | Reiterato | Goldman | Buy |
Mostra tutto
Blueprint Medicines Corp Borsa (BPMC) Ultime notizie
Blueprint Medicines (BPMC) Stock Surges Over 6%, Breaching $100: What's Driving the Rally & What's Next? - Daily Chhattisgarh News
Blueprint Medicines’ SWOT analysis: stock’s potential in precision therapy market - Investing.com
Zacks Research Issues Positive Forecast for BPMC Earnings - Defense World
Insider Sell: Christina Rossi Sells Shares of Blueprint Medicines Corp - GuruFocus
Gotham Asset Management LLC Makes New $309,000 Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug Discovery - Yahoo Finance
Investor Network: Blueprint Medicines Corp. to Host Earnings Call - ACCESS Newswire
Dimensional Fund Advisors LP Has $3.51 Million Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Shares Of Blueprint Medicines Corp (NASDAQ: BPMC): Are They Overvalued Compared To Others? - Stocksregister
Blueprint Medicines Co. (NASDAQ:BPMC) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Insider Sell: Christina Rossi Sells Shares of Blueprint Medicines Corp (BPMC) - GuruFocus
Blueprint Medicines Executives Sell Shares - TradingView
Blueprint Medicines at The Citizens JMP Life Sciences Conference: Strategic Insights - Investing.com
Amarin (NASDAQ:AMRN) & Blueprint Medicines (NASDAQ:BPMC) Financial Survey - Defense World
Blueprint Medicines (NASDAQ:BPMC) Upgraded at StockNews.com - Defense World
Blueprint Medicines’ (BPMC) Buy Rating Reiterated at HC Wainwright - Defense World
Blueprint Medicines Corporation Just Reported A Surprise Profit And Analysts Updated Their Estimates - Yahoo Finance
Blueprint Medicines First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2025 Earnings Call Transcript - Insider Monkey
Blueprint Medicines Corp (BPMC) Stock: A Year of Highs and Lows in the Market - investchronicle.com
BPMC: HC Wainwright & Co. Reiterates Buy Rating on Blueprint Med - GuruFocus
Blueprint Medicines Corp (BPMC) Performance and Fundamentals Dashboard tells a completely different story - Sete News
BPMC: HC Wainwright & Co. Reiterates Buy Rating on Blueprint Medicines | BPMC Stock News - GuruFocus
Blueprint Medicines Corp (BPMC) Q1 2025 Earnings Call Highlights: Strong AYVAKIT Revenue Growth ... - Yahoo Finance
Blueprint Medicines reports Q1 EPS 1c, consensus (44c) - TipRanks
Blueprint Medicines Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Blueprint Medicines Q1 2025 beats EPS, stock rises - Investing.com India
Blueprint Medicines Corp. Reports Strong Earnings Growth - TipRanks
Blueprint Medicines (BPMC) Faces Q1 Revenue Miss, Focuses on Str - GuruFocus
Blueprint Medicines Corp Reports Q1 2025 Earnings: EPS of -$0.56 - GuruFocus
Earnings call transcript: Blueprint Medicines Q1 2025 beats EPS, stock rises By Investing.com - Investing.com South Africa
Blueprint Medicines Corp (NASDAQ: BPMC) Stock Jumping 14.80% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Predicting Blueprint Medicines Corp’s (BPMC) earnings for the current quarter - uspostnews.com
Blueprint Medicines Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Blueprint Medicines Q1 2025 slides: AYVAKIT revenue surges 61%, guidance raised - Investing.com India
Blueprint Medicines: Q1 Earnings Snapshot - marketscreener.com
Blueprint Medicines Corp earnings beat by $0.50, revenue fell short of estimates - Investing.com
Blueprint Medicines Reports First Quarter 2025 Results - TradingView
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - PR Newswire
Blueprint Medicines' Q1 Earnings Decline, Revenue Increases - marketscreener.com
Blueprint Medicines patents new EGFR mutant inhibitors for NSCLC - BioWorld MedTech
Blueprint Medicines (NASDAQ:BPMC) Price Target Cut to $130.00 by Analysts at Needham & Company LLC - Defense World
Needham Adjusts Price Target for Blueprint Medicines (BPMC) Ahea - GuruFocus
What Analysts Are Saying About Blueprint Medicines Stock - Benzinga
Blueprint Medicines stock target cut to $130 at Needham - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Envestnet Asset Management Inc. Buys 3,723 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Announces Q1 2025 Earnings Date: Key Biotech Updates Coming May 1 - Stock Titan
Blueprint Medicines Corp Azioni (BPMC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):